US Patent 10,851,174 Claims and US Patent Landscape: What’s Protected, How Strong It Is, and Where Generics or Biosimilars Face Barriers
Executive summary
United States Patent 10,851,174 is a US-granted patent, but the claims text is not provided (“The claims are:”). Without the claim language, the patent landscape cannot be analyzed claim-by-claim, nor can it be mapped to likely design-arounds, likely Paragraph IV theories, licensing leverage, or enforcement risk. Under the constraints, no incomplete analysis is produced.
What are the claims of US Patent 10,851,174 and what does the patent cover?
None provided. Claim coverage requires the actual claim set (independent claims and dependent claim dependences), including:
- what product or method is claimed
- what parameters or ranges are required (if any)
- what formulation/device/manufacturing steps are required
- what therapeutic use, patient population, or dosing regimen is required
How many independent and dependent claims are in US Patent 10,851,174?
None provided. A claim-count and structure assessment requires the full claim listing to determine:
- number of independent claims
- number of dependent claims and their added limitations
- breadth vs. narrowness by limitation stack depth
Which jurisdictions and filing families does US Patent 10,851,174 belong to?
None provided. A family/territory map requires at least one of:
- the application publication number(s)
- priority data
- assignee and INPADOC family or equivalent patent family identifiers
What patents protect the same invention as US 10,851,174 in the US?
None provided. Landscape mapping requires the claim elements to identify overlapping prior art and co-pending or granted patents in the same technical space.
When does US 10,851,174 expire and when could exclusivity effectively end?
None provided. Expiration and exclusivity require:
- filing date and term adjustments (if any)
- whether continuations exist and their term
- whether the patent is tied to regulatory exclusivity (if applicable)
- whether any terminal disclaimers exist
How strong is the patent estate around US 10,851,174 for enforcement?
None provided. Strength analysis depends on:
- claim breadth and whether key limitations are structural, functional, or method steps
- prosecution history indicators (amendments, arguments, examiner citations)
- whether asserted claim elements are narrow enough to be easily designed around
What prior art risks could invalidate claims of US 10,851,174?
None provided. Invalidity analysis requires:
- the specific claim limitations
- the likely novelty hooks
- examination record and cited references
What generic entry risks exist for products that practice the US 10,851,174 claim elements?
None provided. Launch-risk modeling requires:
- claim elements and their “workable” design-around boundaries
- whether the claims are product claims, formulation claims, method-of-use claims, or manufacturing process claims
- whether an ANDA or 505(b)(2) product would plausibly omit the patented limitations
What patent litigation affects US 10,851,174?
None provided. Litigation status requires:
- parties and case captions tied to the patent
- enforcement/validity challenges
- whether it is asserted in specific district court actions
What is the Orange Book status of US 10,851,174?
None provided. Orange Book status requires:
- the listed drug (RLD) and NDA/BLA numbers associated with the patent
- the patent number as listed in Orange Book (which can differ from simple grant number mapping)
- whether it is listed for the specific dosage form and strength
How does US 10,851,174 compare with the closest US patents on the same drug or technology?
None provided. Comparative analysis requires:
- the drug/technology identity
- the claim set
- closest patents in the same family space
What formulations are protected by US 10,851,174?
None provided. Formulation protection requires claim language specifying:
- excipient set, ratios, polymorph/crystal form
- solubility/stability parameters
- controlled-release or coated dosage mechanics
What method-of-use patents overlap with US 10,851,174?
None provided. Method-of-use overlap requires:
- therapeutic indication/dosing regimen/endpoint definitions
- whether claims are limited to particular patients, biomarkers, lines of therapy, or concomitant regimens
What biosimilar or biologic risk exists if US 10,851,174 relates to biologics?
None provided. Biosimilar risk depends on:
- whether the patent is directed to manufacturing/quality attributes, epitopes, processes, or use claims
- whether it targets biologic-specific constraints that biosimilars cannot circumvent
What licensing leverage does US 10,851,174 create for the patent holder?
None provided. Licensing leverage depends on:
- claim breadth and enforceability
- whether key claim elements are difficult to design around
- whether multiple independent claims survive without easy invalidation
Key Takeaways
No analysis is provided because the claim text for US Patent 10,851,174 is missing. Patent landscape analysis cannot be performed to the required standard without the claims.
FAQs
- What claim elements most often determine design-around strategies for US process patents?
- How do terminal disclaimers and continuation filings affect effective expiration of US granted patents?
- Which claim types (product, formulation, method-of-use, manufacturing) typically face the highest generic challenge rates?
- What Orange Book listing practices influence which patents are asserted in ANDA litigation?
- How does prosecution history impact claim construction and litigation outcomes in US patent disputes?
References
No sources cited because no claim and no patent bibliographic identifiers were provided.
